Estimating time of HIV-1 infection from next-generation sequence diversity

PLoS Computational Biology

Volumn 13, Issue 10, 2017, Pages

  Puller, Vadim ^a,b,c   Neher, Richard ^a,b,c   Albert, Jan ^d,e  

^a MAX PLANCK INSTITUTE FOR DEVELOPMENTAL BIOLOGY   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d KAROLINSKA INSTITUTE   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GENES; VIRUSES;

DATA YIELDS; DIVERSITY MEASURE; GENOMIC REGIONS; HIV-1 INFECTIONS; INFECTED PATIENTS; NEXT-GENERATION SEQUENCING; PAIRWISE DISTANCES; PATIENT VARIATION; POLYMORPHIC SITES; SEQUENCE DIVERSITY;

BIOMARKERS;

BIOLOGICAL MARKER;

ARTICLE; CLINICAL ARTICLE; CODON; DIAGNOSTIC ACCURACY; ENTROPY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MICROBIAL DIVERSITY; NEXT GENERATION SEQUENCING; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL GENE; TIME FACTOR; WHOLE GENOME SEQUENCING; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; HIV INFECTIONS; PROCEDURES; STATISTICAL MODEL; VIROLOGY; VIRUS GENOME;

GENOME, VIRAL; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; MODELS, STATISTICAL; SEQUENCE ANALYSIS, DNA;

EID: 85031911025     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1005775     Document Type: Article

References (42)

1. Le Vu S, Pillonel J, Semaille C, Bernillon P, Le Strat Y, Meyer L, et al. Principles and uses of HIV incidence estimation from recent infection testing—a review. Euro Surveill. 2008;13(36):537–545.
2. Incidence Assay Critical Path Working GroupMore and better information to tackle HIV epidemics: towards improved HIV incidence assays. PLoS Med. 2011;8(6):e1001045. doi: 10.1371/journal.pmed.1001045 21731474
3. World Health OrganizationWhen and how to use assays for recent infection to estimate HIV incidence at a population level. 2011;.
4. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G, Rodriguez W, et al. Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. Aids. 2010;24(18):2763–2771. doi: 10.1097/QAD.0b013e32833f1142 20975514
5. Murphy G, Parry J, Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill. 2008;13(36):314–320.
6. Park SY, Love TM, Nelson J, Thurston SW, Perelson AS, Lee HY, Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS (London, England). 2011;25(16):F13–F19. doi: 10.1097/QAD.0b013e328349f089
7. Moyo S, Vandormael A, Wilkinson E, Engelbrecht S, Gaseitsiwe S, Kotokwe KP, et al. Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in Botswana. PloS One. 2016;11(8):e0160649. doi: 10.1371/journal.pone.0160649 27552218
8. Guy R, Gold J, Calleja JMG, Kim AA, Parekh B, Busch M, et al. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. The Lancet infectious diseases. 2009;9(12):747–759. doi: 10.1016/S1473-3099(09)70300-7 19926035
9. Bärnighausen T, McWalter TA, Rosner Z, Newell ML, Welte A, Review Article: HIV Incidence Estimation Using the BED Capture Enzyme Immunoassay: Systematic Review and Sensitivity Analysis. Epidemiology. 2010; p. 685–697.
10. Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, Hu DJ, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS research and human retroviruses. 2010;26(1):61–71. doi: 10.1089/aid.2009.0133 20063992
11. Lazarus J, Jürgens R, Weait M, Phillips A, Hows J, Gatell J, et al. Overcoming obstacles to late presentation for HIV infection in Europe. HIV medicine. 2011;12(4):246–249. doi: 10.1111/j.1468-1293.2010.00872.x 20807253
12. Sabin CA, Schwenk A, Johnson MA, Gazzard B, Fisher M, Walsh J, et al. Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (London, England). 2010;24(5):723–727.
13. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clinical Infectious Diseases. 2006;42(5):709–715. doi: 10.1086/500213 16447119
14. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds < 200, < 350, and < 500 cells/mm3: assessment of need following changes in treatment guidelines. Clinical infectious diseases. 2011;53(8):817–825. doi: 10.1093/cid/cir494 21921225
15. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K, Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. Journal of the National Cancer Institute. 2010;102(11):784–792. doi: 10.1093/jnci/djq134 20442214
16. Minga A, Lewden C, Gabillard D, Bomisso G, Toni Td, Emième A, et al. CD4 eligibility thresholds: an analysis of the time to antiretroviral treatment in West African HIV-1 seroconverters. AIDS (London, England). 2011;25(6):819–823. doi: 10.1097/QAD.0b013e32834625d3
17. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. Journal of virology. 1999;73(12):10489–10502. 10559367
18. Kouyos R, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, et al. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011;52(4):532–539. doi: 10.1093/cid/ciq164
19. Ragonnet-Cronin M, Aris-Brosou S, Joanisse I, Merks H, Vallée D, Caminiti K, et al. Genetic Diversity as a Marker for Timing Infection in HIV-Infected Patients: Evaluation of a 6-Month Window and Comparison With BED. Journal of Infectious Diseases. 2012;206(5):756–764. doi: 10.1093/infdis/jis411 22826337
20. Andersson E, Shao W, Bontell I, Cham F, Wondwossen A, Morris L, et al. Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infection, Genetics and Evolution. 2013;18:125–131. doi: 10.1016/j.meegid.2013.03.050 23583545
21. Meixenberger K, Hauser A, Jansen K, Yousef KP, Fiedler S, von Kleist M, et al. Assessment of ambiguous base calls in HIV-1 pol population sequences as a biomarker for identification of recent infections in HIV-1 incidence studies. Journal of clinical microbiology. 2014;52(8):2977–2983. doi: 10.1128/JCM.03289-13 24920768
22. Allam O, Samarani S, Ahmad A, Hammering out HIV-1 incidence with Hamming distance. AIDS. 2011;25(16):2047–2048. doi: 10.1097/QAD.0b013e32834bac66 21997490
23. Cousins MM, Konikoff J, Laeyendecker O, Celum C, Buchbinder SP, Seage GR, et al. HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm. Journal of clinical microbiology. 2014;52(1):115–121. doi: 10.1128/JCM.02040-13 24153134
24. Zanini F, Brodin J, Thebo L, Lanz C, Bratt G, Albert J, et al. Population genomics of intrapatient HIV-1 evolution. eLife Sciences. 2016;4:e11282.
25. Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS research and human retroviruses. 2002;18(4):243–248. doi: 10.1089/088922202753472801 11860670
26. Parkin N, Bremer J, Bertagnolio S, Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007–2010. Clinical infectious diseases. 2012;54(suppl 4):S266–S272. doi: 10.1093/cid/cir992 22544186
27. Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. Journal of virological methods. 2009;159(2):185–193. doi: 10.1016/j.jviromet.2009.03.016 19490972
28. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. Aids. 2003;17(13):1871–1879. doi: 10.1097/00002030-200309050-00005 12960819
29. Gaines H, von Sydow M, Pehrson PO, Lundbegh P, Clinical picture of primary HIV infection presenting as a glandular-fever-like illness. Bmj. 1988;297(6660):1363–1368. doi: 10.1136/bmj.297.6660.1363 3146367
30. Cohen MS, Shaw GM, McMichael AJ, Haynes BF, Acute HIV-1 infection. New England Journal of Medicine. 2011;364(20):1943–1954. doi: 10.1056/NEJMra1011874 21591946
31. Skar H, Albert J, Leitner T, Towards estimation of HIV-1 date of infection: a time-continuous IgG-model shows that seroconversion does not occur at the midpoint between negative and positive tests. PLoS One. 2013;8(4):e60906. doi: 10.1371/journal.pone.0060906 23613753
32. Zanini F, Brodin J, Albert J, Neher RA, Error rates, PCR recombination, and sampling depth in HIV-1 Whole Genome Deep Sequencing. Virus research. 2016; 28039047
33. Cock PJA, Antao T, Chang JT, Chapman BA, Cox CJ, Dalke A, et al. Biopython: freely available Python tools for computational molecular biology and. Bioinformatics. 2009;25(11):1422–1423. doi: 10.1093/bioinformatics/btp163 19304878
34. van der Walt S, Colbert SC, Varoquaux G, The NumPy Array: A Structure for Efficient Numerical Computation. Computing in Science Engineering. 2011;13(2):22–30. doi: 10.1109/MCSE.2011.37
35. Hunter JD, Matplotlib: A 2D graphics environment. Computing In Science & Engineering. 2007;9(3):90–95. doi: 10.1109/MCSE.2007.55
36. Nei M, Li WH, Mathematical model for studying genetic variation in terms of restriction endonucleases. Proceedings of the National Academy of Sciences. 1979;76(10):5269–5273. doi: 10.1073/pnas.76.10.5269
37. Zanini F, Puller V, Brodin J, Albert J, Neher RA, In vivo mutation rates and the landscape of fitness costs of HIV-1. Virus. 2017;3:1.
38. Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS (London, England). 2014;28(16):2439. doi: 10.1097/QAD.0000000000000429
39. Sommen C, Commenges D, Vu SL, Meyer L, Alioum A, Estimation of the distribution of infection times using longitudinal serological markers of HIV: implications for the estimation of HIV incidence. Biometrics. 2011;67(2):467–475. doi: 10.1111/j.1541-0420.2010.01473.x 20731647
40. Romero-Severson EO, Lee Petrie C, Ionides E, Albert J, Leitner T, Trends of HIV-1 incidence with credible intervals in Sweden 2002–09 reconstructed using a dynamic model of within-patient IgG growth. International journal of epidemiology. 2015;44(3):998–1006. doi: 10.1093/ije/dyv034 26163684
41. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS pathogens. 2010;6(5):e1000890. doi: 10.1371/journal.ppat.1000890 20485520
42. Redd AD, Quinn TC, Tobian AA, Frequency and implications of HIV superinfection. The Lancet infectious diseases. 2013;13(7):622–628. doi: 10.1016/S1473-3099(13)70066-5 23726798